Eli Lilly and Company (NYSE:LLY) Stock Holdings Lifted by Oliver Lagore Vanvalin Investment Group

Oliver Lagore Vanvalin Investment Group raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 49.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 228 shares of the company’s stock after purchasing an additional 75 shares during the period. Oliver Lagore Vanvalin Investment Group’s holdings in Eli Lilly and Company were worth $78,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Silicon Valley Capital Partners bought a new position in Eli Lilly and Company during the first quarter valued at about $25,000. Bogart Wealth LLC lifted its holdings in Eli Lilly and Company by 193.3% in the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. Laffer Tengler Investments acquired a new stake in Eli Lilly and Company in the 1st quarter worth approximately $33,000. Tanglewood Legacy Advisors LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $37,000. Finally, Freedom Wealth Alliance LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $37,000. Institutional investors own 81.38% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent analyst reports. Morgan Stanley upped their price objective on shares of Eli Lilly and Company from $617.00 to $640.00 and gave the stock an “overweight” rating in a report on Tuesday, September 5th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $500.00 to $615.00 and gave the company an “overweight” rating in a report on Tuesday, August 8th. Royal Bank of Canada lifted their price objective on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. HSBC initiated coverage on Eli Lilly and Company in a research note on Friday, July 14th. They set a “buy” rating and a $560.00 target price for the company. Finally, Barclays lifted their price target on Eli Lilly and Company from $500.00 to $590.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $532.78.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $598.88 on Thursday. The firm has a market capitalization of $568.51 billion, a P/E ratio of 83.29, a P/E/G ratio of 2.36 and a beta of 0.32. The stock has a fifty day moving average price of $504.85 and a two-hundred day moving average price of $433.48. Eli Lilly and Company has a 52-week low of $296.32 and a 52-week high of $601.13. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.13. The business had revenue of $8.31 billion during the quarter, compared to analysts’ expectations of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the company posted $1.25 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 9.83 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were paid a $1.13 dividend. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.75%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Alonzo Weems sold 1,148 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the sale, the executive vice president now owns 7,760 shares in the company, valued at approximately $4,586,004.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Alonzo Weems sold 1,148 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 107,022 shares of the company’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $459.28, for a total value of $49,153,064.16. Following the transaction, the insider now directly owns 101,248,810 shares in the company, valued at approximately $46,501,553,456.80. The disclosure for this sale can be found here. Insiders sold 1,010,309 shares of company stock valued at $21,095,701,670 over the last ninety days. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.